Navigation Links
Pharmasset Receives $10 Million of Working Capital
Date:3/28/2008

nture debt finance company that offers senior and subordinated working capital to emerging technology companies in the information technology and life sciences industries. Horizon provides a compelling alternative to the restrictive structures offered by banks and corporate finance companies.

The Horizon management team has provided debt financing for more than 750 companies over the last 15 years representing more than $2.0 billion in commitments. Horizon has offices in Farmington, CT and Pleasant Hill, CA. For additional information, please go to http://www.HorizonTechFinance.com.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Appoints Herbert J. Conrad as a Director
2. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
3. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
4. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
5. Pharmasset Reports Fiscal Year End 2007 Financial Results
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. Pharmasset to Present at Three Investor Conferences in November 2007
8. Pharmasset Accesses up to $30 Million of Working Capital
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
10. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
11. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  David Hardison, ... ConvergeHEALTH by Deloitte , has been elected chairman ... Standards Consortium, a non-profit working to establish common ... particularly as it relates to electronic health records. ... CDISC,s mission of collaborating with organizations across the ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/28/2014)... The National Model Aviation Museum, located at the ... announce that it has been granted full civilian museum ... Air Force. , The certification is the culmination of ... with an on-site inspection by Sarah Sessions, Museum Certification ... National Museum of the United States Air Force , ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...
... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...
... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...
Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2IsoTis Adjourns Special Meeting to October 23, 2007 3IsoTis Adjourns Special Meeting to October 23, 2007 4CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6
(Date:7/28/2014)... The findings of a new study suggest two ways ... not work as well in obese women, compared to women ... are a one-size-fits-all method, researchers say, but as the population ... the pill works for obese women. Studies have consistently found ... the body, which may in turn affect how well the ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are using ... varying flexibility that can be used as microscale models ... that "bead-spring" polymers, introduced as theory in the 1950s, ... required and should be of interest to materials scientists ... work led by Rice chemical and biomolecular engineer Sibani ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Seeing is bead-lieving 2
... 1, 2008, New York, NY) The Parkinson,s Disease Foundation ... its 2008-2009 International Research Grants and Fellowship Program (IRGFP). ... Parkinson,s scientists, chosen on April 11 from a group ... led by Stanley Fahn, M.D., PDF,s Scientific Director. ...
... Technology shows that coating a titanium implant with a ... growth around the implant and strengthens the attachment and ... "We designed a coating that specifically communicates with cells ... the implant," said Andrs Garca, professor and Woodruff Faculty ...
... Crop yield is highly dependent on soil plant-available water, ... up by plant roots. Quantitative determination of the maximum ... on soil samples remains challenging, especially at the scale ... water capacity for a field would be instrumental in ...
Cached Biology News:The Parkinson's Disease Foundation awards $950,000 in seed grants 2The Parkinson's Disease Foundation awards $950,000 in seed grants 3Researchers coat titanium with polymer to improve integration of joint replacements 2Researchers coat titanium with polymer to improve integration of joint replacements 3Where is your soil water? Crop yield has the answer 2
ChIP-GLAS kit for H10K-B microarray chips. Contains ChIP kit, GLAS kit, and hybridization kit. Additional reagents are required. Please see manual for details. Contains sufficient reagent for 20 reac...
BD BaculoGoldTM Transfection Kit 5 transfections...
...
...
Biology Products: